Geode Capital Management, LLC Cytokinetics Inc Transaction History

Geode Capital Management, LLC

$1.12 Trillion
Q2 2024

A detailed history of Geode Capital Management, LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Geode Capital Management, LLC holds 2,738,646 shares of CYTK stock, worth $141 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,738,646

Previous 2,247,165 21.87%

Holding current value

$141 Million

Previous $158 Million 5.82%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$47.86 - $75.05 $23.5 Million - $36.9 Million	491,481 Added 21.87%	2,738,646 $148 Million
Q1 2024 May 13, 2024	BUY	$63.75 - $108.06 $10 Million - $17 Million	157,040 Added 7.51%	2,247,165 $158 Million
Q4 2023 Feb 13, 2024	BUY	$26.88 - $83.49 $3 Million - $9.33 Million	111,760 Added 5.65%	2,090,125 $175 Million
Q3 2023 Nov 13, 2023	BUY	$29.46 - $36.61 $2.04 Million - $2.53 Million	69,134 Added 3.62%	1,978,365 $58.3 Million
Q2 2023 Aug 11, 2023	BUY	$32.62 - $40.75 $5.69 Million - $7.11 Million	174,535 Added 10.06%	1,909,231 $62.3 Million
Q1 2023 May 15, 2023	BUY	$33.36 - $45.71 $2.56 Million - $3.51 Million	76,846 Added 4.64%	1,734,696 $61 Million
Q4 2022 Feb 13, 2023	BUY	$35.77 - $51.11 $2.37 Million - $3.39 Million	66,392 Added 4.17%	1,657,850 $76 Million
Q3 2022 Nov 14, 2022	BUY	$38.54 - $54.52 $4.16 Million - $5.88 Million	107,936 Added 7.28%	1,591,458 $77.1 Million
Q2 2022 Aug 12, 2022	BUY	$33.93 - $48.92 $393,961 - $568,010	11,611 Added 0.79%	1,483,522 $58.3 Million
Q1 2022 May 13, 2022	BUY	$29.74 - $46.0 $1.29 Million - $1.99 Million	43,289 Added 3.03%	1,471,911 $54.2 Million
Q4 2021 Feb 11, 2022	BUY	$34.35 - $46.38 $1.05 Million - $1.42 Million	30,574 Added 2.19%	1,428,622 $65.1 Million
Q3 2021 Nov 12, 2021	BUY	$18.54 - $35.74 $3.48 Million - $6.71 Million	187,626 Added 15.5%	1,398,048 $50 Million
Q2 2021 Aug 13, 2021	BUY	$19.79 - $26.99 $1.03 Million - $1.41 Million	52,294 Added 4.52%	1,210,422 $24 Million
Q1 2021 May 12, 2021	BUY	$18.57 - $25.68 $1.9 Million - $2.63 Million	102,567 Added 9.72%	1,158,128 $26.9 Million
Q4 2020 Feb 12, 2021	BUY	$15.26 - $28.61 $802,904 - $1.51 Million	52,615 Added 5.25%	1,055,561 $21.9 Million
Q3 2020 Nov 13, 2020	BUY	$20.58 - $28.96 $2.71 Million - $3.82 Million	131,880 Added 15.14%	1,002,946 $21.7 Million
Q2 2020 Aug 13, 2020	BUY	$11.15 - $24.64 $148,406 - $327,958	13,310 Added 1.55%	871,066 $20.5 Million
Q1 2020 May 14, 2020	BUY	$8.75 - $16.3 $505,610 - $941,879	57,784 Added 7.22%	857,756 $10.1 Million
Q4 2019 Feb 13, 2020	BUY	$7.95 - $11.84 $66,008 - $98,307	8,303 Added 1.05%	799,972 $8.49 Million
Q3 2019 Nov 12, 2019	BUY	$10.82 - $14.25 $406,139 - $534,888	37,536 Added 4.98%	791,669 $9.01 Million
Q2 2019 Aug 14, 2019	BUY	$7.95 - $11.25 $659,834 - $933,727	82,998 Added 12.37%	754,133 $8.48 Million
Q1 2019 May 14, 2019	BUY	$5.95 - $10.19 $509,272 - $872,182	85,592 Added 14.62%	671,135 $5.43 Million
Q4 2018 Feb 13, 2019	BUY	$5.91 - $9.29 $419,338 - $659,162	70,954 Added 13.79%	585,543 $3.7 Million
Q3 2018 Nov 13, 2018	BUY	$6.4 - $9.85 $116,089 - $178,669	18,139 Added 3.65%	514,589 $5.07 Million
Q2 2018 Aug 14, 2018	BUY	$6.9 - $9.9 $430,077 - $617,067	62,330 Added 14.36%	496,450 $4.12 Million
Q1 2018 May 15, 2018	BUY	$7.2 - $10.05 $40,118 - $55,998	5,572 Added 1.3%	434,120 $3.13 Million
Q4 2017 Feb 13, 2018	BUY	$7.25 - $15.65 $49,394 - $106,623	6,813 Added 1.62%	428,548 $3.49 Million
Q3 2017 Nov 14, 2017	SELL	$12.0 - $15.0 $318,492 - $398,115	-26,541 Reduced 5.92%	421,735 $6.12 Million
Q2 2017 Aug 14, 2017	BUY	N/A	448,276	448,276 $5.42 Million

Others Institutions Holding CYTK

# of Institutions

408

Shares Held

126M

Call Options Held

3.29M

Put Options Held

2.01M

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $4.85B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Cytokinetics Inc Transaction History